圣达生物(603079) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was ¥184,829,589.97, representing a year-on-year increase of 9.19%[5] - The net profit attributable to shareholders of the listed company was ¥3,813,060.72, reflecting a growth of 9.22% compared to the same period last year[5] - The basic earnings per share for the period was ¥0.02, unchanged from the previous year[5] - Total operating revenue for Q1 2024 was ¥184,829,589.97, an increase of 9.2% compared to ¥169,278,694.33 in Q1 2023[24] - Net profit for Q1 2024 reached ¥5,303,881.02, representing a 62.0% increase from ¥3,271,632.91 in Q1 2023[25] - The company's gross profit margin improved to 4.1% in Q1 2024, compared to 3.0% in Q1 2023[24] - Total operating costs for Q1 2024 were ¥177,350,467.11, up from ¥168,012,041.08 in Q1 2023, reflecting a year-over-year increase of 1.8%[24] Assets and Liabilities - The total assets at the end of the reporting period amounted to ¥1,755,190,749.22, an increase of 2.09% from the end of the previous year[6] - The total assets of the company as of Q1 2024 were ¥1,755,190,749.22, an increase from ¥1,719,185,557.88 in Q1 2023[21] - Total liabilities increased to ¥493,011,209.24 in Q1 2024 from ¥449,195,537.01 in Q1 2023, marking a rise of 9.8%[21] Cash Flow - The net cash flow from operating activities was negative at -¥7,787,016.92, indicating a decrease in cash payments for goods and services[5] - The company's cash flow from operating activities showed a positive trend, indicating improved liquidity[26] - In Q1 2024, the cash inflow from operating activities was CNY 190,560,812.44, an increase of 5.8% compared to CNY 180,236,939.85 in Q1 2023[27] - The cash outflow from operating activities decreased to CNY 198,347,829.36 from CNY 230,012,747.88, resulting in a net cash flow from operating activities of -CNY 7,787,016.92, an improvement from -CNY 49,775,808.03 in the previous year[27] - Investment activities generated a net cash outflow of -CNY 84,570,309.38, compared to -CNY 57,724,177.90 in Q1 2023, indicating increased investment expenditures[28] - Cash inflow from financing activities increased to CNY 57,000,000.00 in Q1 2024, up from CNY 47,600,000.00 in Q1 2023[28] - The net cash flow from financing activities improved to CNY 33,430,862.39 from CNY 17,206,071.00 year-over-year[28] - The ending cash and cash equivalents balance decreased to CNY 247,275,484.71 from CNY 260,029,482.88 in the previous year[28] Shareholder Information - The company reported a total of 23,738 common shareholders at the end of the reporting period[10] - The largest shareholder, Zhejiang Shengda Group Co., Ltd., holds 26.51% of the shares, amounting to 45,375,792 shares[10] Future Plans - The company plans to continue expanding its product sales to drive revenue growth in the upcoming quarters[8] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[26] - The company plans to issue up to 51,356,687 A-shares to raise a total of no more than RMB 500 million for production projects, including 3 billion soft capsules and 3 billion solid preparations[12] Government Support - The company received government subsidies amounting to ¥1,326,002.63, which are closely related to its normal business operations[7] Share Repurchase - The company has repurchased a total of 1,872,500 shares, accounting for 1.09% of the total share capital, with a total expenditure of RMB 22,078,434.00[16] - The maximum repurchase price per share was RMB 13.38, while the minimum was RMB 7.428[16] Regulatory Updates - The company received a second round of inquiry from the Shanghai Stock Exchange regarding its stock issuance application on January 7, 2024[14] - The company has updated its fundraising documents in response to inquiries from the Shanghai Stock Exchange, with the latest updates disclosed on November 4, 2023[13]